Silencing of synaptotagmin 13 inhibits tumor growth through suppressing proliferation and promoting apoptosis of colorectal cancer cells

Li,Qin; Zhang,Shun; Hu,Miao; Xu,Ming; Jiang,Xiaohua

doi:10.3892/ijmm.2019.4412

Silencing of synaptotagmin 13 inhibits tumor growth through suppressing proliferation and promoting apoptosis of colorectal cancer cells

Authors:
- Qin Li
- Shun Zhang
- Miao Hu
- Ming Xu
- Xiaohua Jiang
View Affiliations

Affiliations: Department of Gastroenterology, Shanghai East Hospital, Tongji University, Shanghai 200123, P.R. China, Department of Gastrointestinal Surgery, Shanghai East Hospital, Tongji University, Shanghai 200123, P.R. China
Published online on: November 26, 2019 https://doi.org/10.3892/ijmm.2019.4412
Pages: 234-244
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The treatment of colorectal cancer is currently hampered by the lack of early detection technology. The identification of molecular biomarkers for colorectal cancer is crucial for improving prognosis. Synaptotagmin (SYT) 13 has been reported to be associated with several human tumors, but its role in colorectal cancer remains elusive. In the present study, immunohistochemistry was utilized to detect the expression of SYT13 in colorectal cancer tissues and cells. MTT, colony formation, wound healing and Transwell assays were conducted to evaluate the effect of SYT13 knockdown on the biological behavior of RKO and HCT116 cells. Cell apoptosis and cell cycle profiles were detected by FACS. A mouse xenograft model was constructed to investigate the effect of SYT13 on colorectal cancer in vivo. The results indicated that SYT13 was upregulated in colorectal tumor tissues compared with paracancerous tissues. Silencing of SYT13 inhibited the proliferation, colony formation, migration and invasion ability of RKO and HCT116 cells. Moreover, SYT13 knockdown arrested the cell cycle in the G2 phase, thus inducing cell apoptosis. The in vivo experiments also demonstrated the inhibitory effect of SYT13 on tumor growth. In conclusion, the present study demonstrated that SYT13 may act as a promoter in the development and progression of colorectal cancer and, therefore, may be of value as a target for the development of novel treatment strategies.

View Figures

View References

1	Haggar FA and Boushey RP: Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar :
2	Lao VV and Grady WM: Epigenetics and colorectal cancer. Nat Rev Gastro Hepat. 8:686–700. 2011. View Article : Google Scholar
3	Martenson JA, Haddock MG and Gunderson LL: Cancers of the Colon, Rectum, and Anus. Springer Berlin Heidelberg. 34:545–559. 2006.
4	Weitz J, Koch M, Debus J, Höhler T, Galle PR and Büchler MW: Colorectal cancer. Lancet. 365:153–165. 2005. View Article : Google Scholar : PubMed/NCBI
5	Migliore L, Migheli F, Spisni R and Coppedè F: Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol. 2011:7923622011. View Article : Google Scholar : PubMed/NCBI
6	Pox CP: Controversies in colorectal cancer screening. Digestion. 89:274–281. 2014. View Article : Google Scholar : PubMed/NCBI
7	Lieu C and Kopetz S: The SRC family of protein tyrosine kinases: A new and promising target for colorectal cancer therapy. Clin Colorectal Cancer. 9:89–94. 2010. View Article : Google Scholar : PubMed/NCBI
8	Lin JS, Piper MA, Perdue LA, Rutter CM, Webber EM, O'Connor E, Smith N and Whitlock EP: Screening for colorectal cancer: Updated evidence report and systematic review for the US preventive services task force. JAMA. 315:2576–2594. 2016. View Article : Google Scholar : PubMed/NCBI
9	Pang ZP and Südhof TC: Cell biology of Ca2⁺-triggered exocytosis. Curr Opin Cell Biol. 22:496–505. 2010. View Article : Google Scholar : PubMed/NCBI
10	Fernández-Chacón R, Königstorfer A, Gerber SH, García J, Matos MF, Stevens CF, Brose N, Rizo J, Rosenmund C and Südhof TC: Synaptotagmin I functions as a calcium regulator of release probability. Nature. 410:41–49. 2001. View Article : Google Scholar : PubMed/NCBI
11	Brose N, Petrenko AG, Südhof TC and Jahn R: Synaptotagmin: A calcium sensor on the synaptic vesicle surface. Science. 256:1021–1025. 1992. View Article : Google Scholar : PubMed/NCBI
12	Sutton RB, Davletov BA, Berghuis AM, Sudhof TC and Sprang SR: Structure of the first C2 domain of synaptotagmin I: A novel Ca2⁺/phospholipid-binding fold. Cell. 80:929–938. 1995. View Article : Google Scholar : PubMed/NCBI
13	Perin MS, Fried VA, Mignery GA, Jahn R and Südhof TC: Phospholipid binding by a synaptic vesicle protein homologous to the regulatory region of protein kinase C. Nature. 345:260–263. 1990. View Article : Google Scholar : PubMed/NCBI
14	Fukuda M and Mikoshiba K: Characterization of KIAA1427 protein as an atypical synaptotagmin (Syt XIII). Biochem J. 354:249–257. 2001. View Article : Google Scholar : PubMed/NCBI
15	Von CP and Südhof TC: Synaptotagmin 13: Structure and expression of a novel synaptotagmin. Eur J Cell Biol. 80:41–47. 2001. View Article : Google Scholar
16	Rickman C, Craxton M, Osborne S and Davletov B: Comparative analysis of tandem C2 domains from the mammalian synaptotagmin family. Biochem J. 378:681–686. 2004. View Article : Google Scholar : PubMed/NCBI
17	Grønborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, Sato N, Molina H, Jensen ON, Hruban RH, Goggins MG, et al: Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics. 5:157–171. 2006. View Article : Google Scholar
18	Jahn JE and Coleman WB: Re-expression of tumorigenicity after attenuation of human synaptotagmin 13 in a suppressed micro-cell hybrid cell line. Int J Oncol. 32:441–449. 2008.PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
20	László L: Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. Magy Onkol. 54:383–394. 2010. View Article : Google Scholar : PubMed/NCBI
21	Kulendran M, Stebbing JF, Marks CG and Rockall TA: Predictive and prognostic factors in colorectal cancer: A personalized approach. Cancers (Basel). 3:1622–1638. 2011. View Article : Google Scholar
22	Chen TH, Chang SW, Huang CC, Wang KL, Yeh KT, Liu CN, Lee H, Lin CC and Cheng YW: The prognostic significance of APC gene mutation and miR-21 expression in advanced-stage colorectal cancer. Colorectal Dis. 15:1367–1374. 2013. View Article : Google Scholar : PubMed/NCBI
23	Falchook GS and Kurzrock R: VEGF and dual-EGFR inhibition in colorectal cancer. Cell Cycle. 14:1129–1130. 2015. View Article : Google Scholar : PubMed/NCBI
24	Xiao J, Lv D, Zhou J, Bei Y, Chen T, Hu M, Zhou Q, Fu S and Huang Q: Therapeutic inhibition of miR-4260 suppresses colorectal cancer via targeting MCC and SMAD4. Theranostics. 7:1901–1913. 2017. View Article : Google Scholar : PubMed/NCBI
25	Koga Y, Yasunaga M, Takahashi A, Kuroda J, Moriya Y, Akasu T, Fujita S, Yamamoto S, Baba H and Matsumura Y: MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res (Phila). 3:1435–1442. 2010. View Article : Google Scholar
26	Huang Z, Huang DS, Ni S, Peng Z, Sheng W and Du X: Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 127:118–126. 2010. View Article : Google Scholar
27	Li D, Yan D, Tang H, Zhou C, Fan J, Li S, Wang X, Xia J, Huang F, Qiu G and Peng Z: IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol. 16:3499–3506. 2009. View Article : Google Scholar : PubMed/NCBI
28	Lin L, Zhang J, Wang Y, Ju W, Ma Y, Li L and Chen L: Insulin-like growth factor-II mRNA-binding protein 3 predicts a poor prognosis for colorectal adenocarcinoma. Oncol Lett. 6:740–744. 2013. View Article : Google Scholar : PubMed/NCBI
29	Johnson CP: Emerging functional differences between the synaptotagmin and ferlin calcium sensor families. Biochemistry. 56:6413–6417. 2017. View Article : Google Scholar : PubMed/NCBI
30	Mizuta M, Inagaki N, Nemoto Y, Matsukura S, Takahashi M and Seino S: Synaptotagmin III is a novel isoform of rat synaptotagmin expressed in endocrine and neuronal cells. J Biol Chem. 269:11675–11678. 1994.PubMed/NCBI
31	Grise F, Taib N, Monterrat C, Lagrée V and Lang J: Distinct roles of the C(2)A and the C2B domain of the vesicular Ca2⁺ sensor synaptotagmin 9 in endocrine beta-cells. Biochem J. 403:483–492. 2007. View Article : Google Scholar : PubMed/NCBI
32	Andersson SA, Olsson AH, Esguerra JL, Heimann E, Ladenvall C, Edlund A, Salehi A, Taneera J, Degerman E, Groop L, et al: Reduced insulin secretion correlates with decreased expression of exocytotic genes in pancreatic islets from patients with type 2 diabetes. Mol Cell Endocrinol. 364:36–45. 2012. View Article : Google Scholar : PubMed/NCBI
33	Sreenath AS, Kumar KR, Reddy GV, Sreedevi B, Praveen D, Monika S, Sudha S, Reddy MG and Reddanna P: Evidence for the association of synaptotagmin with glutathione S-transferases: Implications for a novel function in human breast cancer. Clin Biochem. 38:436–443. 2005. View Article : Google Scholar : PubMed/NCBI
34	Thierry-Mieg D and Thierry-Mieg J: AceView: A comprehensive cDNA-supported gene and transcripts annotation. Genome Biol. 7(Suppl 1): S122006. View Article : Google Scholar : PubMed/NCBI
35	Han S, Hong S, Lee D, Lee MH, Choi JS, Koh MJ, Sun W, Kim H and Lee HW: Altered expression of synaptotagmin 13 mRNA in adult mouse brain after contextual fear conditioning. Biochem Biophys Res Commun. 425:880–885. 2012. View Article : Google Scholar : PubMed/NCBI
36	Keck KJ, Breheny P, Braun TA, Darbro B, Li G, Dillon JS, Bellizzi AM, O'Dorisio TM and Howe JR: Changes in gene expression in small bowel neuroendocrine tumors associated with progression to metastases. Surgery. 163:232–239. 2018. View Article : Google Scholar
37	Jahn JE, Best DH and Coleman WB: Exogenous expression of synaptotagmin XIII suppresses the neoplastic phenotype of a rat liver tumor cell line through molecular pathways related to mesenchymal to epithelial transition. Exp Mol Pathol. 89:209–216. 2010. View Article : Google Scholar : PubMed/NCBI
38	Zhu H, Wu TC, Chen WQ, Zhou LJ, Wu Y, Zeng L and Pei HP: Screening for differentially expressed genes between left- and right-sided colon carcinoma by microarray analysis. Oncol Lett. 6:353–358. 2013. View Article : Google Scholar : PubMed/NCBI